| You
are here: Home: Web
Guide 02- Surgeons: Gabriel
N Hortobagyi, MD: Select publications
Select publications
Use of aromatase inhibitors in
the adjuvant setting
Anastrozole alone or in combination with tamoxifen versus
tamoxifen alone for adjuvant treatment of postmenopausal women with
early breast cancer: First results of the ATAC randomised trial.
Lancet 2002;359(9324):2131-9. Abstract
Pharmacokinetics of anastrozole and tamoxifen alone, and
in combination, during adjuvant endocrine therapy for early breast
cancer in postmenopausal women: A sub-protocol of the ‘Arimidex
and tamoxifen alone or in combination’ (ATAC) trial.
Br J Cancer 2001;85(3):317-24. Abstract
Baum M. The ATAC (Arimidex, Tamoxifen, Alone or in Combination)
adjuvant breast cancer trial in postmenopausal patients: Factors
influencing the success of patient recruitment. Eur J Cancer
2002;38(15):1984. Abstract
Baum M. A vision for the future? Br J Cancer
2001;85 Suppl 2:15-8. Abstract
Bianco AR. ATAC (‘Arimidex’, Tamoxifen, Alone
or in Combination) trial — Anastrozole is superior to tamoxifen
as adjuvant treatment in postmenopausal women with early breast
cancer. Breast Cancer Res Treat 2002;Abstract
632.
Buzdar A. The ATAC (‘Arimidex’, Tamoxifen,
Alone or in Combination) trial in postmenopausal women with early
breast cancer — Updated efficacy results based on a median
follow-up of 47 months. Breast Cancer Res Treat 2002;Abstract
13.
Buzdar AU. New generation aromatase inhibitors —
From the advanced to the adjuvant setting. Breast Cancer
Res Treat 2002;75 Suppl 1:S13-7; discussion S33-5. Abstract
Buzdar AU. Anastrozole (Arimidex) — An aromatase
inhibitor for the adjuvant setting? Br J Cancer 2001;85
Suppl 2:6-10. Abstract
Goss PE. Preliminary data from ongoing adjuvant aromatase
inhibitor trials. Clin Cancer Res 2001;7(12 Suppl):4397s-4401s;
discussion 4411s-4412s. Abstract
Jones SE. Antiaromatase agents: Evolving role in adjuvant
therapy. Clin Breast Cancer 2002;3(1):33-42. Abstract
Mokbel K. The evolving role of aromatase inhibitors in
breast cancer. Int J Clin Oncol 2002;7(5):279-83. Abstract
Ragaz J. Adjuvant trials of aromatase inhibitors: Determining
the future landscape of adjuvant endocrine therapy. J Steroid
Biochem Mol Biol 2001;79(1-5):133-41. Abstract
Sainsbury R. Beneficial side-effect profile of anastrozole
compared with tamoxifen confirmed by additional 7 months of exposure
data: A safety update from the ’Arimidex’, Tamoxifen,
Alone or in Combination (ATAC) trial. Breast Cancer Res
Treat 2002;Abstract
633.
Wellington K, Faulds DM. Anastrozole in early breast cancer.
Drugs 2002;62(17):2485-92. Abstract
Winer EP et al. American Society of Clinical Oncology
technology assessment on the use of aromatase inhibitors as adjuvant
therapy for women with hormone receptor-positive breast cancer:
Status report 2002. J Clin Oncol 2002;20(15):3317-27. Abstract
|
